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Introduction
At each mitosis, cells face the tremendous challenge of separating 
the sister chromatids in two identical pools. This process, on which 
all cells rely to remain viable, is usually executed with great   
accuracy. Its perturbation results in aberrations in chromosome 
numbers (aneuploidies), which are a cause of disease and cor­
relate with cellular transformation (Weaver and Cleveland, 2006).
Fidelity of cell division is the result of feedback controls. 
The first control mechanism halts the process of cell division 
and imposes a mitotic arrest when chromosome–microtubule   
attachment is perturbed in different ways (for review see Rieder   
and Palazzo, 1992). This ability of eukaryotic cells activates a 
checkpoint (for reviews see Hartwell and Weinert, 1989; McIntosh, 
1991; Rieder and Palazzo, 1992), generally known as the spindle 
assembly checkpoint (for review see Musacchio and Salmon, 
2007) and herewith often abbreviated as spindle checkpoint or 
simply checkpoint. The checkpoint cannot be satisfied under 
conditions that perturb chromosome–microtubule attachment, 
most typically the depolymerization of microtubules (lack of   
attachment). In humans, spindle checkpoint components include 
enzymes such as the BUB1, BUBR1, MPS1, and PRP4 kinases 
and protein–protein interaction devices such as BUB3, MAD1, 
MAD2, and the three­subunit ROD–ZWILCH–ZW10 (RZZ) 
complex (for review see Musacchio and Salmon, 2007).
During prometaphase, the checkpoint proteins are recruited   
to unattached kinetochores, which are large protein assemblies 
built on chromosomal loci known as centromeres (Cleveland   
et al., 2003). An 550­kD, 10­subunit assembly, the KMN   
network (from the initials of its subcomplexes the Knl1, Mis12, 
and Ndc80 complexes), provides the microtubule­binding core 
of the outer kinetochore (Cheeseman et al., 2006; for review see 
Santaguida and Musacchio, 2009). Kinetochore recruitment of 
the checkpoint proteins is an obligatory condition for sustained 
checkpoint signaling. Its impairment invariably leads to a failure 
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he catalytic activity of the MPS1 kinase is crucial for 
the spindle assembly checkpoint and for chromosome 
biorientation on the mitotic spindle. We report that 
the small molecule reversine is a potent mitotic inhibitor of 
MPS1. Reversine inhibits the spindle assembly checkpoint 
in  a  dose-dependent  manner.  Its  addition  to  mitotic   
HeLa cells causes the ejection of Mad1 and the ROD– 
ZWILCH–ZW10 complex, both of which are important for 
the spindle checkpoint, from unattached kinetochores.   
By using reversine, we also demonstrate that MPS1 is   
required for the correction of improper chromosome– 
microtubule attachments. We provide evidence that MPS1 
acts downstream from the AURORA B kinase, another 
crucial component of the error correction pathway. Our 
experiments describe a very useful tool to interfere with 
MPS1 activity in human cells. They also shed light on the 
relationship between the error correction pathway and 
the spindle checkpoint and suggest that these processes 
are coregulated and are likely to share at least a subset of 
their catalytic machinery.
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which these proteins may contribute to these functions are being 
actively investigated. For instance, it was recently proposed that 
MPS1 acts upstream of AURORA B to control AURORA B 
function in biorientation (Jelluma et al., 2008b).
Reversine, a 2,6­disubsituted purine, has been originally 
identified for its ability to facilitate the dedifferentiation of C2C12   
myoblasts into multipotent cells capable of redifferentiating into 
different cell types (Chen et al., 2004, 2007). Recently, this 
property of reversine was attributed to its ability to inhibit the 
AURORA B kinase (D’Alise et al., 2008; Amabile et al., 2009). 
This spurred our interest in testing the mitotic effects of reversine, 
and we set out to test whether reversine had additional mitotic 
targets besides AURORA B. In the course of this analysis, we 
realized that reversine is a very potent and relatively selective 
ATP­competitive inhibitor of human MPS1. The mitotic effects 
of reversine are consistent with the possibility that MPS1 is its 
principal target in mitosis. Our results demonstrate that MPS1 
is indeed a checkpoint component required for the recruitment 
of other checkpoint proteins, including the subunits of the RZZ 
complex and MAD1–MAD2, to unattached kinetochores. We 
also show that MPS1 is implicated in biorientation and in error 
correction. Our results are consistent with a model in which 
MPS1 operates downstream from AURORA B and suggest that 
the error correction and the spindle checkpoint may respond to 
a single upstream sensor designed to detect lack of attachment 
and reduced or missing tension.
Results
Reversine is a potent MPS1 inhibitor
Reversine has been shown to target AURORA kinases in vitro 
and in living cells (D’Alise et al., 2008; Amabile et al., 2009). 
To assess the potency of reversine on AURORA kinases, we 
compared its effects with those of known AURORA inhibi­
tors. Reversine inhibited AURORA B in vitro with an IC50 of   
98.5 nM, 30­fold and twofold above the IC50 of hesperadin 
and ZM447439, respectively (Fig. 1 A; Fig. S1, A and B; and 
Table S1). In contrast, AURORA A was inhibited with an IC50 
of 876 nM (Fig. S1, A and B; and Table S1).
To ascertain whether reversine is a selective AURORA B 
inhibitor, we set up an in vitro kinase assay with a battery of 
human mitotic kinases, including BUB1, CDK1–CYCLIN B, 
HASPIN, MPS1, NEK2A, PLK1, PRP4, and TAO1 (Fig. 1 B 
and Table S1). At 1 µM, reversine failed to alter the activity of 
all but one of these kinases. The MAPKs, which have also been 
implicated in mitotic control in vertebrates (e.g., Zhao and Chen, 
2006), are not significantly inhibited at 1 µM reversine (D’Alise 
et al., 2008). The only kinase in our dataset to be effectively   
inhibited by reversine is MPS1, with an IC50 of 6 nM and 2.8 nM   
for its kinase domain and full­length versions, respectively   
(Fig. 1, C and D). The latter IC50 value indicates 35­fold selectiv­
ity over AURORA B in vitro (both kinases were tested at 50 µM   
ATP). As a comparison, we found that SP600125, which has 
been previously shown to inhibit MPS1 (Schmidt et al., 2005), 
has an IC50 for MPS1 of 2.5 µM (Fig. S1 C and Table S1). 
Surprisingly, we also found that this inhibitor has a significantly 
lower IC50 for AURORA B (Fig. S1 D and Table S1).
in the checkpoint response (for examples and discussions see 
Meraldi et al., 2004).
Spindle checkpoint activity converges on the generation 
of an anaphase­promoting complex/cyclosome (APC/C) in­
hibitor known as the mitotic checkpoint complex (for review 
see Musacchio and Salmon, 2007). Mad2, BubR1, and Bub3 
contribute in different ways to the formation of the mitotic 
checkpoint complex. Cdc20, the target of the checkpoint pro­
teins in the mitotic checkpoint complex, is a positive regula­
tor of the APC/C, an ubiquitin­ligase whose activity is required 
for  progression  into  anaphase.  By  inhibiting  Cdc20,  the 
spindle checkpoint prevents APC/C activation toward crucial 
substrates for anaphase such as Cyclin B and Securin and, 
consequently,  mitotic  exit  (for  review  see  Musacchio  and 
Salmon, 2007).
The second control mechanism, generally referred to as   
error correction, prevents the stabilization of kinetochore– 
microtubule attachments until they come under tension (Nicklas   
and Koch, 1969; Li and Nicklas, 1995). Improper kinetochore– 
microtubule attachments such as merotelic or syntelic attach­
ments are probably distinguished from proper attachments 
(amphitelic attachment or biorientation) and corrected because   
they are not under full tension. The molecular basis of sta­
bilization or destabilization of improper attachments is being 
actively investigated. The first protein to become clearly impli­
cated in this process was the AURORA B kinase (for review see   
Ruchaud et al., 2007). AURORA B is a member of the AURORA   
family of S/T kinases, which also includes the ubiquitously 
expressed AURORA A, which is involved in spindle bipolar­
ization, and AURORA C, whose role is poorly understood but 
likely limited to meiosis and early development (for review 
see Ruchaud et al., 2007). AURORA B is part of the chromo­
some passenger complex, whose subunits also include INCENP,   
SURVIVIN, and BOREALIN (for review see Ruchaud et al., 
2007). Inactivation of Ipl1, the only AURORA kinase in Saccha-
romyces cerevisiae, leads to the stabilization of syntelic attach­
ments, implicating Ipl1 in their correction (Tanaka et al., 2002). 
In vertebrates, inhibition of AURORA B by small molecules 
or RNAi leads to the accumulation of merotelic and syntelic   
attachments (Ditchfield et al., 2003; Hauf et al., 2003; Lampson   
et al., 2004; Cimini et al., 2006; Knowlton et al., 2006). The   
regulation of microtubule­destabilizing enzymes known as 
MCAK (mitotic centromere–associated kinase) and KIF2B 
by AURORA B may be important for correction (for reviews 
see Pinsky and Biggins, 2005; Vader and Lens, 2008; Kelly 
and Funabiki, 2009). Furthermore, AURORA B phosphory­
lates NDC80, a subunit of the KMN network, on at least six 
to eight sites near the microtubule­binding interface, causing 
a strong decrease of microtubule­binding affinity (Cheeseman 
et al., 2006; DeLuca et al., 2006; Ciferri et al., 2008; Guimaraes   
et  al.,  2008;  Miller  et  al.,  2008).  Thus,  stabilization  of   
kinetochore–microtubule attachment might be concomitant with 
NDC80 dephosphorylation.
Besides being implicated in the spindle assembly check­
point, BUB1, BUBR1, and MPS1 have also been shown to take 
part in biorientation and possibly in error correction (for review 
see  Kang  and Yu,  2009).  The  detailed  mechanisms  through 75 Reversine is an MPS1 inhibitor • Santaguida et al.
Reversine did not inhibit kinetochore fiber formation, as 
assessed with a cold treatment microtubule depolymerization 
assay (Fig. S2 E). However, reversine had strong effects on chromo­
some congression. Many chromosomes failed to congress to the 
metaphase plate in the presence of reversine, a phenotype which 
was clearly visible already at 250 nM reversine (Fig. 2, A–C; and 
Fig. S2, A–D).
Based on previous analyses, the reversine phenotype is 
consistent with inhibition of MPS1 in mammalian cells (Jelluma 
et al., 2008b; Tighe et al., 2008). However, the phenotype is also 
reminiscent of phenotypes created by bona fide AURORA B 
Mitotic phenotypes of reversine
Next, we tried to determine a working concentration of reversine 
that would inhibit MPS1 but not AURORA kinases. Inhibition 
of AURORA A or the Eg5 kinesin prevents spindle bipolarization, 
resulting in a monopolar spindle (Glover et al., 1995). Contrarily 
to the Eg5 inhibitor S­trityl­l­cysteine (STLC) and the pan­ 
AURORA inhibitor VX680, used as positive controls, reversine 
did not inhibit spindle bipolarization at concentrations up to   
10 µM (Fig. 2, A and B; and Fig. S2, A–D). Thus, AURORA A 
is unlikely to be a cellular target of reversine at concentrations 
up to 10 µM or above.
Figure 1.  Reversine inhibits MPS1 in vitro. (A) A kinase assay on the human AURORA B
1–344–INCENP
835–903 complex with the indicated concentrations of 
reversine. The substrate is histone H3. (B) The indicated recombinant, purified mitotic kinases were tested with the indicated substrates for their sensitivity 
to 1 µM reversine (Rev). None of the kinases were significantly inhibited. Specific inhibitors against PLK1 (BI2536) and CDK1 (roscovitine) were used as 
positive controls. (C and D) A reversine titration experiment on the kinase domain of MPS1 (C) or full-length MPS1 (D). The substrate is the MAD1–MAD2 
complex (Sironi et al., 2001). Molecular mass is indicated in kilodaltons. (A, C, and D) Error bars are mean ± SEM. AR, autoradiography; CBB, Coomassie 
brilliant blue staining; Ctrl, control; CYCB, CYCLIN B.JCB • VOLUME 190 • NUMBER 1 • 2010   76
(Fig. 2 E and see Fig. 4 D). With hesperadin, P­S10­H3 was 
strongly inhibited between 10 and 50 nM (Fig. 2 E).
We also tested the effects on cytokinesis, a stringent assay 
for AURORA B activity (Fig. 2 F). In the 5–10 nM range, hes­
peradin impaired cytokinesis in 100% of cells. Similar effects were 
observed in the 0.1–0.5 µM concentration range of ZM447439.   
However, cytokinesis appeared unaffected at 1 µM reversine and 
was only impaired at higher concentrations.
To test a possible compensatory role of AURORA A, which,   
as shown in Fig. S1 (A and B) and Table S1, is only modestly 
inhibited by reversine in vitro and does not appear to be inhib­
ited in living cells by the criterion that spindles are bipolar, 
we lowered the levels of AURORA A by RNAi and tested the 
inhibitors  such  as  hesperadin  and  ZM447439  (Fig.  S2  B; 
Ditchfield et al., 2003; Hauf et al., 2003). To assess the relative 
contribution of AURORA B or MPS1 inhibition to the chromo­
some congression problems described in the previous paragraph, 
we asked whether reversine affected other cellular functions 
known to implicate AURORA B activity. By immunofluores­
cence, the phosphorylation of Ser10 of H3 (P­S10­H3), a bona 
fide AURORA B substrate, was visible until concentrations   
of reversine >5 µM, whereas the same signal disappeared at   
significantly lower concentrations of hesperadin or ZM447439 
(Fig. 2 D). Similarly, by Western blotting, reversine inhibited 
P­S10­H3 only at concentrations >2–5 µM, whereas ZM447439 
affected significant inhibition of P­S10­H3 already at 500 nM 
Figure 2.  Submicromolar reversine does not inhibit Aurora B in living cells. (A) Reversine does not prevent spindle bipolarization, but several chromo-
somes fail to congress (arrowheads). 7 h (numbers above arrows indicate time in hours) after a single thymidine arrest (STA), STLC (an Eg5 inhibitor causing 
spindle monopolarization) or reversine was added, and after an additional 0.5 h, MG132 was added to prevent mitotic exit. After 1.5 h, cells were then 
processed for immunofluorescence (IF). (B) Quantification of the experiment in A on the indicated number of cells. (C) Quantification of alignment defects 
in the same experiment. (D) After release from a single thymidine arrest, cells entered mitosis in the presence of reversine (Rev), hesperadin (Hesp), and 
ZM447439 (ZM) and were fixed and subjected to immunofluorescence to monitor the levels of P-S10-H3. (E) A comparison of the effects of the inhibitors 
tested in D on the levels of P-S10-H3 in total cell lysates of mitotic HeLa cells. (F) The effects of the same three inhibitors on cytokinesis were evaluated in   
a time-lapse experiment. (B, C, and F) Error bars are mean ± SEM. (G and H) AURORA A (AUR A) does not contribute to the generation of P-S10-H3. Under 
conditions of RNAi of AURORA A, the disappearance of P-S10-H3 in the presence of reversine (H) followed the same pattern as in the control experiments 
(G). A similar experiment testing the effects on P-S7–CENP-A is reported in Fig. S4 B. Dashed lines highlight the disappearance of AURORA A in H as the 
result of RNAi. Ctrl, control; CYC B1, CYCLIN B1; Noco, nocodazole; WB, Western blot. Bars, 5 µm.77 Reversine is an MPS1 inhibitor • Santaguida et al.
Similarly, reversine does not significantly inhibit cytokinesis at 
0.5 µM (Fig. 2 F). Overall, these results strongly suggest that 
MPS1 does not exercise a strong direct control over AURORA B 
activity. In agreement with this idea, the kinetochore levels of 
P–CENP­A were not influenced at concentrations of reversine up 
to 5 µM or above (Fig. 4 A and Fig. S4) and were also not inhib­
ited upon MPS1 RNAi (Fig. 4, A and B). Incidentally, it is worth 
noting that these experiments were performed in nocodazole, i.e., 
in the presence of unattached kinetochores. The presence of an 
intense P–CENP­A signal in nocodazole and its disappearance 
in the presence of an AURORA B inhibitor such as hesperadin 
(Fig. S4) shows that, in agreement with a recent study (Liu et al., 
2009), AURORA B is active on unattached kinetochores.
We also assessed whether reversine or MPS1 RNAi influ­
enced the localization of AURORA B. In either case, we failed to 
observe defects in the localization of AURORA B (Fig. 4 C).   
Furthermore, the presence of reversine did not influence the state   
of activation of AURORA B, as monitored by activation loop auto­
phosphorylation (P­T232), at least until concentrations at which   
reversine appeared to hit AURORA B directly (Fig. 4 D).
We monitored MPS1 localization in the presence of rever­
sine and/or hesperadin. In unperturbed mitoses (not depicted)   
or in nocodazole (Fig. 4 E), we observed a significant cytosolic   
signal and relatively weak MPS1 kinetochore staining. However, 
strong kinetochore staining was observed when MPS1 activity was 
inhibited with 0.5 µM reversine. This result is inconsistent with   
a recent report that autophosphorylation of MPS1 is required 
for kinetochore localization (Xu et al., 2009). Inhibition of 
AURORA B with 0.5 µM hesperadin prevented kinetochore   
localization of MPS1 in nocodazole, as well as the kinetochore 
enrichment of MPS1 caused by reversine (Fig. 4 E). Similar   
results were obtained with 100 nM hesperadin at 3.3 µM   
nocodazole (Fig. S5). These results indicate that AURORA B 
may be required for kinetochore localization of MPS1.
Both reversine and hesperadin reduced the mitotic phos­
phorylation of MPS1 (Fig. 4 F). This was unlikely to be caused 
by a direct effect of hesperadin on MPS1 because we failed to ob­
serve significant MPS1 (and BUB1) inhibition at 1 µM hesperadin 
in vitro (Fig. 4 G). Collectively, the experiments in Fig. 4 sup­
port the idea that MPS1 acts downstream of AURORA B rather 
than upstream, as recently proposed (Jelluma et al., 2008b).
Role of MPS1 in error correction
The work so far demonstrates that MPS1 is important for bi­
orientation, which is in agreement with previous observations 
(Jones et al., 2005; Maure et al., 2007; Jelluma et al., 2008b; 
Tighe et al., 2008). We wished to exploit the availability of a 
small molecule inhibitor of MPS1 to test whether this kinase is 
implicated in error correction. For this, we applied an assay pre­
viously developed to test the implication of AURORA B in error 
correction (Lampson et al., 2004). HeLa cells were first treated 
with the Eg5 inhibitor STLC to induce a monopolar spindle 
and a large number of kinetochore–microtubule attachment   
errors (Fig. 5 A). Cells were then allowed to recover by washing 
out the Eg5 inhibitor in the presence of MG132. Control cells 
formed a bipolar spindle. If the recovery phase was performed 
in the presence of reversine to inhibit MPS1 or ZM447439 
effects of reversine on P­S10­H3 (Fig. 2, G and H). This condi­
tion failed to exacerbate the effect of reversine on P­S10­H3, 
excluding the hypothesis that AURORA A compensates for 
AURORA B when reversine is present.
Collectively,  these  results  justify  the  conclusion  that   
inhibition of AURORA B is unlikely to be the cause of the effects 
of submicromolar concentrations of reversine in mitotic HeLa 
cells. Therefore, we decided to carry out additional character­
ization experiments on the effects of reversine at a reference 
working concentration of 0.5 µM or else at the concentrations 
indicated in each figure.
Reversine and RNAi of MPS1 produce 
similar phenotypes
To corroborate the idea that the observed effects of reversine 
can be ascribed to the inhibition of MPS1, we performed a   
systematic comparison of the effects from using 0.5 µM reversine 
or from ablating MPS1 by RNAi. Because the addition of 0.5 µM   
reversine or MPS1 depletion by RNAi overrides the spindle 
checkpoint response to 0.33 µM nocodazole (see Fig. 6), cells 
were kept in mitosis with 10 µM MG132. At least macroscopi­
cally, reversine and MPS1 RNAi caused identical alignment 
phenotypes (Fig. 3 A). No obvious additive effects on chromo­
some alignment from combining MPS1 RNAi with reversine 
were observed, suggesting that MPS1 is a target of submicro­
molar concentrations of reversine or, alternatively, that the target 
of reversine works in the same pathway as MPS1.
We extended the comparison to the localization of an   
array of a dozen centromere and kinetochore markers, includ­
ing subunits of the inner and outer kinetochore, of the RZZ 
complex, and of the spindle checkpoint (Fig. 3, B and C; and   
Fig. S3). The experiments were performed in the presence of 
0.33 µM nocodazole and MG132. In control cells, these condi­
tions prevented satisfaction of the spindle checkpoint, and all 
checkpoint proteins were recruited to kinetochores (Fig. 3 B). 
Neither reversine nor RNAi treatment affected kinetochore   
recruitment of KMN network subunits, indicating that reversine 
does not grossly perturb the structure of the outer kinetochore 
(Fig. 3, B and C; Fig. S3; and not depicted).
We next tested the effects from adding reversine on MPS1 
phosphorylation, which correlates with its mitotic activation (Kang 
et al., 2007; Mattison et al., 2007; Jelluma et al., 2008a; Xu   
et al., 2009). In agreement with the idea that MPS1 is a target of 
reversine, we observed a dose­dependent reversal of the electro­
phoretic mobility of MPS1, which reflects autophosphorylation 
(Fig. 3, D and E; Kang et al., 2007; Mattison et al., 2007; Jelluma 
et al., 2008a). At 0.5 µM reversine, a concentration that completely 
inhibits MPS1 autophosphorylation, no effects on P­S10­H3 were 
observed. Similarly, we did not observe effects on the level of 
P­S10­H3 upon RNAi­based depletion of MPS1 (Fig. 3 F).
MPS1 acts downstream of AURORA B
Our results so far suggest that reversine is an MPS1 inhibitor in 
vitro and in vivo. They also demonstrate that reversine does not 
cause a prominent reduction in the levels of P­S10­H3 in living 
cells at concentrations (e.g., 0.5 µM) that cause substantial problems 
in chromosome biorientation and on MPS1 autophosphorylation. JCB • VOLUME 190 • NUMBER 1 • 2010   78
Of  note,  although  the  P–CENP­A  signal  disappeared  in 
ZM447439, no inhibition of P–CENP­A was evident in the pres­
ence of reversine, indicating that the target of reversine in error 
correction is unlikely to be, or to act upstream of, AURORA B   
to inhibit AURORA B, bipolar spindles also formed, but several   
misaligned chromosomes were evident (as quantified in Fig. 5 B).   
Thus, both MPS1 and AURORA B activity are required to re­
cover from the attachment errors induced by monopolarization.   
Figure 3.  Reversine inhibits MPS1 in living cells. (A) Chromosome alignment phenotypes of mitotic HeLa cells that were depleted of MPS1 by RNAi or 
treated with 0.5 µM reversine (Rev), or both. The levels of P-S10-H3 appeared unaltered in all three experiments. A representative RNAi-based depletion of 
MPS1 is shown in F. (B) Representative localization experiments on different kinetochore proteins including CREST, CENP-C, MAD1, and SPINDLY (Griffis 
et al., 2007; Chan et al., 2009). Results from the complete analysis are summarized in C and in Fig. S3. (A and B) Numbers above arrows indicate 
time in hours. (C) The RZZ subunits ROD, ZWILCH, and ZW10, as well as the RZZ-associated protein SPINDLY and MAD1 are all largely evicted from 
kinetochores when the spindle checkpoint is triggered with 330 nM nocodazole (Noco), with no significant difference between MPS1 RNAi or reversine 
treatment. The effects on localization are expressed as ratios of the fluorescence value of the indicated protein to the value of CREST (both background 
subtracted) normalized to the equivalent ratio in control cells. Error bars are mean ± SEM. (D) Dose-dependent inhibition of MPS1 phosphorylation in the 
presence of reversine. Vinculin (VINC) was used as a loading control. (E) Dose-dependent inhibition of MPS1. Samples were separated on an 8% gel with 
the PHOS tag method (Kinoshita et al., 2006). (F) Western blotting demonstrates that P-S10-H3 levels are untouched upon MPS1 RNAi or inhibition with 
reversine. The hesperadin control illustrates the effects from inhibiting AURORA B (AUR B). Ctrl, control; CYC B, CYCLIN B; DTA, double thymidine arrest; 
IF, immunofluorescence; WB, Western blot. Bars, 5 µm.79 Reversine is an MPS1 inhibitor • Santaguida et al.
checkpoint components such as MAD2 and BUBR1 (e.g., Meraldi 
et al., 2004). This was confirmed in experiments in which cells 
were treated with concentrations of nocodazole (0.33 µM or   
3.3 µM) that cause partial or complete microtubule depolymeri­
zation, respectively (Fig. 7 A; Brito et al., 2008). The addition 
of reversine caused a dose­dependent reduction in the timing of 
mitotic arrest, and the override was complete at 1.0 µM rever­
sine at either concentration of nocodazole (Table S2). At lower 
concentrations of reversine, the effects on the duration of the 
checkpoint were more explicit at 0.33 µM nocodazole. Similar 
trends were observed with AURORA kinase inhibitors (Table S2). 
Checkpoint overriding by reversine was not limited to HeLa 
in this pathway. At 1 µM, ZM447439 did not inhibit MPS1 in vitro   
(Table S1). After washout of ZM447439 or reversine, normal meta­
phases with properly aligned chromosomes formed, indicating that 
the targets of these inhibitors are required for error correction. 
Overall, these results implicate MPS1, like AURORA B, in the 
correction of improper kinetochore–microtubule attachments.
Effects of reversine on  
cell cycle progression
As expected for an MPS1 inhibitor, reversine caused HeLa cells 
to exit mitosis prematurely during an unperturbed mitosis (Fig. 6 A),   
as  demonstrated  previously  for  the  ablation  of  additional 
Figure  4.  MPS1  acts  downstream  from   
Aurora  B.  (A)  P-S7–CENP-A  in  mitotic  HeLa 
cells is unaltered even at 5 µM reversine (Rev). 
The antigen is present on centromeres/kineto-
chores of chromosomes near the poles, as well 
as of chromosomes at the equator. The antigen 
is invisible in the presence of 100 nM hespera-
din (Hesp). No compensation from Aurora A 
was  observed  (Fig.  S4  B).  (B)  A  quantifica-
tion of the results in A. “S” and “W” indicate 
strong and weak binding, respectively. These 
criteria are indicated in Fig. S4 A. Error bars 
are  mean  ±  SEM.  (C)  Kinetochore  localiza-
tion of AURORA B (AUR B) in HeLa cells is 
unaffected after MPS1 RNAi or the addition 
of reversine. (D, top) Phosphorylation of the 
activation loop of AURORA B (P-T232) is not 
affected by reversine until above 2 µM. The 
pattern of loss of activation loop phosphory-
lation follows the pattern of loss of P-S10-H3 
phosphorylation.  (bottom)  The  same  experi-
ment with ZM447439 (ZM) as a positive con-
trol. (E) Kinetochore localization of MPS1 in 
660 nM nocodazole (Noco) is enhanced by 
0.5 µM reversine. If AURORA B is inhibited 
with 0.5 µM hesperadin, reversine-induced   
localization  of  MPS1  is  abrogated.  Images 
were  taken  on  a  Delta  Vision  microscope. 
The insets represent 10× zooms of the boxed 
areas  interpolated  using  SoftWoRx.  (F)  Both 
MPS1 and AURORA B inhibitors reduce the 
phosphorylation  of  mitotic  MPS1,  as  visual-
ized through the PHOS tag method (Kinoshita 
et al., 2006). (A and C–F) Numbers above   
arrows indicate time in hours. (G) Hesperadin 
does not inhibit BUB1 or MPS1 in an in vitro 
kinase assay (see also Table S1). Molecular 
mass is indicated in kilodaltons. Ctrl, control; 
DTA, double thymidine arrest; IF, immunofluores-
cence; WB, Western blot. Bars, 5 µm.JCB • VOLUME 190 • NUMBER 1 • 2010   80
and Salmon, 2007). A consequence of the artificial stabilization 
of kinetochore–microtubule attachment when the error correction 
pathway is inhibited is that the levels of checkpoint proteins at 
kinetochores are strongly reduced (Yang et al., 2009). To demon­
strate beyond reasonable doubt that the inhibition of MPS1 causes 
a genuine checkpoint override rather than a mere satisfaction of the 
spindle checkpoint in the absence of error correction, as has been 
previously proposed for AURORA B inhibitors (Yang et al., 2009), 
we monitored the recruitment of the checkpoint proteins, an estab­
lished hallmark of checkpoint activity, to kinetochores at 3.3 µM 
nocodazole (Fig. 7 A). Even at 3.3 µM nocodazole, both the RZZ 
and MAD1 were unable to localize to kinetochores (Fig. 7, B–D). 
Thus, the disappearance of checkpoint proteins from kinetochores 
when MPS1 is inhibited is not caused by satisfaction of the spindle 
checkpoint by residual kinetochore–microtubules in the absence 
of an error correction mechanism. Rather, this behavior reflects a 
genuine requirement of MPS1 in kinetochore recruitment of a sub­
set of checkpoint components.
Reversine does not inhibit MEK1, 
nonmuscle Myosin II (NMMII), or 
phosphatidyl-inositol 3-kinase (PI3K)  
in mitosis
After their initial characterization of reversine in the dedifferentia­
tion of lineage­committed mouse­derived C2C12 myoblasts (Chen 
et al., 2004), Chen et al. (2007) identified NMMII, MEK1, and 
PI3K as putative targets of reversine. Although our characterization 
of reversine strongly supports inhibition of MPS1 as the main 
mechanism of reversine action in mitosis, we wished to test the 
possibility that NMMII, MEK1, or PI3K are targets of reversine 
during mitosis.
The effects of blebbistatin, an NMMII inhibitor (Straight   
et al., 2003), were compared with the effects of reversine. At 100 µM,   
blebbistatin did not cause any evident effects on chromosome align­
ment, suggesting that NMMII, the target of this inhibitor, does not 
contribute to chromosome alignment (Fig. 8 A). Blebbistatin did 
not significantly affect the ability of mitotic HeLa cells to maintain 
a nocodazole­mediated arrest (unpublished data). Because rever­
sine does not have obvious effects on cytokinesis until concentra­
tions of 2–5 µM, at which concentrations we show that it inhibits 
Aurora B (Fig. 2 F), we surmise that the mitotic phenotypes caused 
by submicromolar reversine are unlikely to be the result of the in­
hibition of NMMII and that if NMMII inhibition occurs, it does so 
at concentrations of reversine >2–5 µM. To assess whether NMMII 
is a target of reversine at high concentration in mitotic cells, it will 
be necessary to sort out the relative effects of reversine on Aurora B 
and NMMII, as both of these proteins work in cytokinesis.
We also compared the effects from adding MEK1 or PI3K 
inhibitors to the ability of HeLa cells to maintain a nocodazole­ 
mediated arrest. Neither the MEK inhibitor U0126 nor the PI3K 
inhibitor wortmannin affected the duration of the spindle check­
point in the presence of spindle poisons (Fig. 8, B and C). Overall, 
these results indicate that NMMII, MEK1, and PI3K are not promi­
nent mitotic targets of reversine or else that their inhibition by   
reversine does not cause a prominent mitotic phenotype. In agree­
ment with a previous study (Stucke et al., 2004), we also failed to 
see an effect of reversine on centrosome duplication (Fig. 8 D).
cells, as it was also observed with comparable potency in U2OS 
and retinal pigment epithelial cells (Fig. 6 C). Reversine also 
caused an override of the checkpoint in the presence of Taxol, 
STLC, or the Plk1 inhibitor BI2536 (Fig. 6, D and E).
MPS1 is required for localization of 
checkpoint proteins when microtubules are 
completely depolymerized
Kinetochore­bound microtubules contribute to removing the 
checkpoint proteins from kinetochores (for review see Musacchio 
Figure 5.  MPS1 is involved in error correction. (A) Cycling HeLa cells were 
treated with STLC for 12 h. Most cells arrest in mitosis with a monopolar 
spindle. After STLC washout in MG132, control cells bipolarize and form 
a normal metaphase. If STLC washout is performed in the presence of re-
versine (Rev) or ZM447439 (ZM), the spindle bipolarizes normally, but a 
large fraction of improper attachments are visible. P-S7–CENP-A, a bona 
fide AURORA B substrate, appears unaltered in reversine-treated cells but 
disappears in ZM447439. After removal of the inhibitors, a metaphase 
plate forms. P-S7–CENP-A reappears after washout of ZM447439. In vitro, 
2 µM ZM447439 does not inhibit MPS1 (Table S1 and not depicted). 
(B) Quantification of results with number of cells monitored in the experi-
ment. Error bars are mean ± SEM. Bar, 5 µm.81 Reversine is an MPS1 inhibitor • Santaguida et al.
with  the  effects  from  ablating  MPS1  by  RNAi  implies  that 
MPS1 is the main mitotic target of reversine. Inhibition of   
additional targets in other cell cycle phases and in postmitotic 
cells may be responsible for the dedifferentiation function of 
reversine (Chen et al., 2004).
Our analysis indicates that the catalytic activity of MPS1 
is implicated both in error correction and in the spindle check­
point.  We  hypothesize  that  the  error  correction  and  spindle 
checkpoint pathways intersect at MPS1 when its kinase activity 
becomes activated at kinetochores so that substrates in both 
pathways  become  concomitantly  phosphorylated.  Although   
we support this hypothesis, it is formally possible that MPS1 is   
selectively activated to phosphorylate targets relevant to error 
correction or to the spindle checkpoint under different condi­
tions (e.g., lack of attachment or reduced tension in the presence 
of attachment). Future studies will be required to distinguish 
between these two models.
Discussion
In this study, we have demonstrated a role for the small mol­
ecule reversine in the mitotic inhibition of MPS1. After the dis­
covery of cincreasin as an MPS1 inhibitor in budding yeast (Dorer 
et al., 2005), reversine now provides a small molecule tool for   
interfering with the spindle checkpoint in human cells, flanking 
additional recently described MPS1 inhibitors (Kwiatkowski   
et al., 2010; see Hewitt et al. in this issue). We show that rever­
sine inhibits AURORA B in mitosis but at concentrations that 
are incompatible with the observed adverse effects of submicro­
molar reversine on biorientation, error correction, and the spindle 
checkpoint. However, the reported accumulation of polyploid 
cells  at  micromolar  concentrations  of  reversine  (presumably 
caused by a failure in cytokinesis) is consistent with AURORA B   
inhibition (D’Alise et al., 2008). Our systematic comparison of 
the effects from using reversine at submicromolar concentrations   
Figure 6.  Reversine is a spindle checkpoint inhibitor. (A) Reversine (Rev) causes normally cycling HeLa cells to exit mitosis prematurely, which is a con-
sequence of spindle checkpoint inactivation. The plot is a quantification of a time-lapse video microscopy experiment. (B) As in A, the experiment quantifies 
the behavior of cells in time-lapse video microscopy experiments in which HeLa cells were treated with two concentrations of nocodazole (Noco). Additional 
values (including controls) are collected in Table S2. (C) The ability of reversine to drive HeLa cells out of mitosis extends to at least two additional cell types. 
(A–C) Error bars are mean ± SEM. (D) The ability of HeLa cells to arrest in mitosis in the presence of 500 nM Taxol or 10 µM STLC was tested in a time-
lapse experiment in the presence of reversine. 12 h after the beginning of the video, control cells treated with Taxol or STLC were still in mitosis, whereas 
the presence of reversine caused a spindle assembly checkpoint override and mitotic exit. (E) Similar experiments were performed in the presence of the 
Polo kinase inhibitor BI2536, which causes a mitotic arrest (Lénárt et al., 2007). In this case, time 0 refers to the last video frame before mitotic rounding 
up. (D and E) Numbers above arrows indicate time in hours. Ctrl, control; NEBD, nuclear envelope breakdown. Bars, 10 µm.JCB • VOLUME 190 • NUMBER 1 • 2010   82
specifically positioned fluorescence markers within the kineto­
chore, projected onto the interkinetochore axis, increases up to   
35–40 nm (Maresca and Salmon, 2009; Uchida et al., 2009; Wan   
et al., 2009). These changes may reflect a distortion in the struc­
ture of kinetochores caused by the application of a physical force 
(tension) upon microtubule binding. Alternatively, they may   
reflect a conformational change in the kinetochore triggered by 
microtubule binding. The first hypothesis is reinforced by the 
observation that microtubule binding is by itself insufficient 
to cause full intrakinetochore stretching and that dynamic micro­
tubules are required for full stretching (Maresca and Salmon, 
2009, 2010).
The AURORA B kinase has emerged as a key regulator of 
the error correction pathway. It has been proposed that AURORA B   
may monitor variations in the distance from its substrates as   
microtubules attach to kinetochores (Tanaka et al., 2002;  Andrews 
et al., 2004). Strong experimental evidence in favor of this idea is 
emerging (Vader et al., 2007; Liu et al., 2009, 2010; Welburn et al.,   
2010). Tension exerted by bound microtubules may contribute to 
the gradual displacement of substrates from AURORA B, re­
sulting in turn in substrate dephosphorylation. We have recently 
proposed  a  speculative  model  picturing  INCENP  as  a  “dog 
leash” whose limited extension limits the ability of AURORA B   
Among the mechanisms through which MPS1 may con­
tribute to biorientation and error correction is the ability of MPS1 
to regulate the motor activity of CENP­E, a plus end–directed 
motor that crucially contributes to chromosome congression 
(Espeut et al., 2008). Furthermore, the ablation of kinetochore 
recruitment of the RZZ complex in the absence of MPS1 activ­
ity likely prevents kinetochore recruitment of Dynein, which 
also contributes to kinetochore–microtubule attachment (for 
review see Musacchio and Salmon, 2007). In yeast, Mps1 regu­
lation of biorientation may proceed through phosphorylation 
of the subunits of the Dam1 and Ndc80 complexes (Shimogawa   
et al., 2006; Maure et al., 2007; Kemmler et al., 2009). However, 
MPS1 may control the spindle checkpoint by contributing, among 
additional functions, to kinetochore recruitment of the RZZ 
complex and MAD1.
It is important to characterize the hierarchical relationships 
at the apex of the sensory apparatus that distinguished correct 
from incorrect attachments and that ignites the error correction 
and  checkpoint  responses.  Two  recent  studies  demonstrated   
that intrakinetochore stretch upon microtubule binding, as   
opposed to interkinetochore stretch, correlates with the status of 
the checkpoint response (Maresca and Salmon, 2009; Uchida 
et al., 2009). Upon microtubule binding, the distance between 
Figure 7.  MPS1 is required for kinetochore recruitment of the RZZ and MAD1 even in high nocodazole. (A) Immunofluorescence analysis of the distribu-
tion of TUBULIN (TUB) in the presence of 0.33 and 3.3 µM nocodazole (Noco). Residual foci of polymerized TUBULIN are visible in 0.33 µM nocodazole 
but not in 3.3 µM nocodazole. HeLa cells were incubated in the presence of nocodazole for 15 min before fixation for immunofluorescence. (B) 5 h after 
release from a double thymidine arrest, reversine (Rev; at the indicated concentrations) and nocodazole (0.33 or 3.3 µM) were added. MAD1 failed to 
localize to kinetochores at either nocodazole concentration. (C) The same experimental scheme as in B was used under conditions of RNAi-based deple-
tion of MPS1. (D) The histogram summarizes results on localization experiments equivalent to those in B and C on MAD1 and the additional indicated 
kinetochore proteins. Localization data were quantified as in Fig. 3 C. Error bars are mean ± SEM. Bars, 5 µm.83 Reversine is an MPS1 inhibitor • Santaguida et al.
to reach its substrates within the kinetochore (for review see 
Santaguida and Musacchio, 2009). Previous experiments with a 
deletion mutant of INCENP are indeed consistent with this idea   
(Vader et al., 2007).
We  provide  evidence  that  AURORA  B  acts  upstream 
of MPS1 and that the perturbation of MPS1 activity does not 
grossly alter the phosphorylation of AURORA B substrates or 
the localization of AURORA B. Similar results are reported in 
an accompanying paper describing the effects from targeting 
an analogue­sensitized allele of MPS1 (see Maciejowski et al. 
in this issue). Similarly, no effects on the levels of AURORA B   
substrates are observed with an additional MPS1 inhibitor, 
AZ3146 (Hewitt et al., 2010). If inhibition of MPS1 does 
not result in overt changes in AURORA B activity, we show   
instead that inhibition of AURORA B causes a mislocalization 
of MPS1 and a reduction of its phosphorylation, suggesting that 
AURORA B acts upstream of MPS1. This possibility is also 
consistent with the pattern of recruitment of spindle checkpoint 
proteins in different systems (Vigneron et al., 2004; Famulski 
and Chan, 2007; Emanuele et al., 2008). Because MPS1 turns 
over rapidly at kinetochores (Howell et al., 2004), its activation 
at kinetochores, which probably involves dimerization and auto­
phosphorylation (Kang et al., 2007; Mattison et al., 2007;   
Jelluma et al., 2008a), may precede its release in the cytosol in 
an active form.
Overall, these results may appear inconsistent with the   
recent proposal that MPS1 controls AURORA B through phos­
phorylation of BOREALIN, a subunit of the chromosome 
passenger complex (Jelluma et al., 2008b; Kwiatkowski et al., 
2010; Sliedrecht et al., 2010). Because a phospho­mimicking 
mutant  of  BOREALIN  simulating  MPS1  phosphorylation   
rescues the effects on biorientation from loosing MPS1 (Jelluma 
et al., 2008b), MPS1 and BOREALIN may participate in an 
AURORA B–independent pathway implicated in biorientation. 
More studies will be required to assess this idea.
If MPS1, which is implicated in error correction and in the 
checkpoint, acts downstream from AURORA B and is activated 
by it, then AURORA B is also expected to control both error 
correction and the spindle checkpoint. Although the involve­
ment of AURORA B in error correction is widely accepted, its 
participation in the spindle checkpoint is more controversial.   
In at least two model systems, Schizosaccharomyces pombe  
and Xenopus laevis, Aurora B is required for the checkpoint   
response  to  unattached  kinetochores  (Kallio  et  al.,  2002;   
Petersen and Hagan, 2003; Vanoosthuyse and Hardwick, 2009). 
Direct involvement of AURORA B in checkpoint signaling has 
also been observed upon expression of an INCENP mutant   
deleted of the coiled­coil domain of INCENP (Vader et al., 
2007). This mutant does not affect the ability of AURORA B to 
Figure 8.  Reversine does not inhibit NMMII, MEK1, PI3K, or centrosome 
duplication. (A) At 100 µM, blebbistatin (Bleb) does not cause evident 
perturbations of chromosome alignment, contrarily to 1 µM reversine 
(Rev). (B) At 10 µM, the MEK1 inhibitor U0126 does not affect the dura-
tion of the spindle checkpoint. (C) At 100 nM, the PI3K inhibitor wort-
mannin (Wortm) does not affect the duration of the spindle checkpoint.   
(B and C) Error bars are mean ± SEM. (D) Cells arrested with a double   
thymidine arrest (DTA) procedure were released in the cell cycle, and the 
number of centrosomes was measured in the subsequent mitosis. In all 
cases, two centrosomes were measured, indicating that centrosome du-
plication takes place normally in the presence of reversine. (A, B, and D) 
Numbers above arrows indicate time in hours. Ctrl, control; IF, immunofluores-
cence; STA, single thymidine arrest. Bars, 5 µm.
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involvement to become explicit. We show that at least in vitro, 
these higher concentrations of hesperadin do not inhibit BUB1 
and MPS1, but it remains formally possible that hesperadin 
inhibits additional kinases in the MAD1 and RZZ recruitment 
pathway. We conclude that a formal assessment of the role of 
AURORA B in the checkpoint response will require more pen­
etrant and selective inhibition of AURORA B.
Materials and methods
Cell culture and synchronization
HeLa cells and U2OS cells were grown in DME (EuroClone) supple-
mented with 10% fetal bovine serum (HyClone) and 2 mM l-glutamine. 
Human telomerase reverse transcriptase–retinal pigment epithelial cells 
were grown in minimal essential medium: Ham’s F12K medium 1:1 
supplemented with 10% fetal bovine serum, 15 mM Hepes, and 0.5 mM   
Na pyruvate. 0.33 and 3.3 µM nocodazole, 0.5 µM Taxol, 5 µM STLC, 
and 2 mM thymidine were obtained from Sigma-Aldrich. MG132 (EMD) 
was used at 10 µM.
RNAi
siRNA duplexes used to repress AURORA A, AURORA B, BUB1, BUBR1, and   
MPS1 (Ditchfield et al., 2003) had the following sequences: AURORA A, 
5-AAGCACAAAAGCUUGUCUCCA-3; AURORA B, 5-AACGCGGCA-
CUUCACAAUUGA-3; BUB1, 5-AAAUACCACAAUGACCCAAGA-3; 
BUBR1, 5-AACGGGCAUUUGAAUAUGAAA-3; and MPS1, 5-GACAGAU-
GAUUCAGUUGUA-3. siRNA duplexes were purchased from Thermo Fisher   
Scientific and transfected using Lipofectamine 2000 reagent (Invitrogen) 
according to the manufacturer’s instructions.
Immunofluorescence microscopy and antibodies for immunofluorescence
In all cases except Fig. 4 E, immunofluorescence microscopy was per-
formed on cells fixed using 4% PFA in PBS, permeabilized using 0.1% Tri-
ton X-100 in PBS, and then treated with 4% BSA in PBS as blocking agent 
and incubated with the proper antibodies diluted in 4% BSA in PBS. For 
MPS1 staining, cells grown on coverslips were washed in PBS, fixed in 1% 
formaldehyde for 5 min, quenched in glycine, pH 8.5, and then permeabi-
lized with PBS plus 0.1% Triton X-100 (PBST) before incubation with pri-
mary and secondary antibodies (Taylor et al., 2001; Tighe et al., 2008; 
Trazzi et al., 2009).
The following antibodies were used for immunofluorescence: anti-
centromeric antibody (working dilution 1:50; Antibodies Inc.), mouse 
anti-HEC1 (human NDC80; working dilution 1:1,000; clone 9G3.23; 
GeneTex, Inc.), mouse anti–-TUBULIN (working dilution 1:2,000; clone 
B512;  Sigma-Aldrich),  rabbit  anti-SPINDLY  (working  dilution  1:250; 
Bethyl  Laboratories,  Inc.);  rabbit  anti–AURORA  B  (working  dilution 
1:1,000; Abcam), rabbit anti–PS10-H3 (working dilution 1:500; Abcam), 
and rabbit anti-P-S7–CENP-A Ser7 (working dilution 1:300; Abcam). 
Antibodies against BUB1, BUBR1, CENP-C, MAD1, MPS1, ZW10, and 
ZWILCH have been described previously (Taylor et al., 2001; De Antoni 
et al., 2005; Tighe et al., 2008; Trazzi et al., 2009; Civril et al., 2010).   
Antibody against ROD was a gift from T.J. Yen (Fox Chase Cancer   
Center, Philadelphia, PA). Antibodies against MIS12 and KNL1 were 
a gift from T. Kiyomitsu and M. Yanagida (Kyoto University, Sakyo-ku, 
Kyoto,  Japan).  Cy3-  and  Cy5-labeled  and  Alexa  Fluor  488–labeled 
secondary  antibodies  for  immunofluorescence  were  purchased  from 
Jackson ImmunoResearch Laboratories, Inc. and Invitrogen, respectively. 
DNA was stained with DAPI. The coverslips were mounted using Mowiol 
mounting media.
Cells were imaged using a confocal microscope (TCS SP2; Leica) 
equipped with a 63× NA 1.4 objective lens using the LCS 3D software 
(Leica). Images were imported in Photoshop CS3 (Adobe Systems, Inc.), 
and levels were adjusted. Pixel intensity quantification has been performed 
using SoftWoRx (Applied Precision).
For Fig. 4 E, immunofluorescence images were acquired at room 
temperature on a restoration microscope (Delta Vision RT; Applied Preci-
sion) using a 100× NA 1.40 Plan-Apochromat objective and the Sedat 
Quad filter set (Chroma Technology Corp.). The images were collected 
using a charge-coupled device camera (CoolSNAP HQ; Photometrics) with 
a z-optical spacing of 0.2 mm. Raw images were then deconvolved using 
the SoftWoRx software, and maximum intensity projections of these decon-
volved images are shown.
phosphorylate some of its centromeric substrates, suggesting that 
it is impairing a specific function of the chromosome passenger 
complex in spindle checkpoint control (Vader et al., 2007).
In many additional settings, including experiments with 
yeast temperature­sensitive mutants (Biggins and Murray, 2001) 
or small molecule inhibitors (Ditchfield et al., 2003; Hauf et al., 
2003), the inhibition of AURORA B has been shown to reduce 
the strength of the checkpoint arrest to unattached kinetochores 
but not to lead to complete override. It is possible that these   
effects result from residual AURORA B activity as a conse­
quence of incomplete depletion or inactivation. Small residual 
AURORA B activity may be sufficient to maintain the arrest 
under the strong checkpoint­activating conditions created by 
spindle­depolymerizing agents. However, the requirements on 
MPS1 may be more stringent, explaining why it is relatively 
easier to observe a checkpoint override when targeting MPS1.
A  confusing  aspect  of  the  relationship  between  error 
correction and the spindle checkpoint is that the inhibition of 
error correction can influence the pattern of kinetochore local­
ization  of  the  spindle  checkpoint  proteins  and  therefore  the 
strength of the checkpoint response at suboptimal concentra­
tions of spindle­depolymerizing drugs such as nocodazole 
(Brito et al., 2008; Yang et al., 2009). Evidence of this can be 
extrapolated from Fig. 6 B: the same concentration of reversine   
(i.e., the same expected degree of target kinase inhibition) has 
significantly different effects on the duration of mitotic arrest at 
low or high nocodazole doses. Thus, residual microtubules may 
contribute to checkpoint satisfaction if kinetochores cannot let 
go of them because error correction is impaired (Yang et al., 
2009). A pathway that removes the checkpoint proteins from 
microtubule­bound  kinetochores  (for  review  see  Musacchio 
and Salmon, 2007) is likely responsible for this phenomenon. 
Future studies will have to refer to the rigorous test proposed 
by Yang et al. (2009) for evaluating the participation of MPS1, 
AURORA B, and other proteins in the checkpoint response. The 
test consists in evaluating the effects from ablating a putative 
checkpoint component when spindle­depolymerizing drugs are 
present at concentrations (3.2 µM nocodazole or more in HeLa 
cells) that remove any residual tubulin polymer. By applying 
this test to AURORA B, Yang et al. (2009) demonstrated that at 
100 nM hesperadin, the presence or absence of residual micro­
tubules results in dramatic differences in the localization of the 
checkpoint protein MAD2 to kinetochores. At high nocodazole 
concentrations (3.2 µM), MAD2 is retained on kinetochores   
despite the presence of hesperadin. Conversely, at low nocodazole 
concentrations and at the same concentration of hesperadin, 
MAD2 is absent from kinetochores (Yang et al., 2009).
This  result  predicts  that  previous  studies  implicating 
AURORA B in MAD2 recruitment might have been at least 
in part biased by the relatively low nocodazole concentrations 
used (e.g., Ditchfield et al., 2003; Hauf et al., 2003). However, 
we find that at higher hesperadin concentrations (0.5–1.0 µM), 
MAD1 (which is required for MAD2 recruitment) and the RZZ 
complex are lost from kinetochores even at high concentrations 
of nocodazole (unpublished data). Thus, AURORA B may   
be ultimately required for the recruitment of these checkpoint 
proteins, but higher levels of inhibition may be required for its 85 Reversine is an MPS1 inhibitor • Santaguida et al.
Online supplemental material
Fig. S1 shows additional kinase assays. Fig. S2 shows the characterization 
of the alignment phenotypes of different inhibitors. Fig. S3 shows addi-
tional kinetochore localization experiments. Fig. S4 shows that the levels of 
P-S7–CENP-A are not affected by reversine. Fig. S5 shows that AURORA B 
inhibition prevents accumulation of kinetochore MPS1. Table S1 shows 
IC50 values (in nM) for the combination of different inhibitors and kinases. 
Table S2 shows the duration of mitosis in cells treated with spindle poisons 
and kinase inhibitors. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.201001036/DC1.
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Antibodies for immunoblotting
The following antibodies were used for immunoblotting: mouse anti– 
AURORA  A  (working  dilution  1:1,000;  Sigma-Aldrich),  rabbit  anti– 
AURORA B (working dilution 1:1,000; Abcam), rabbit anti-BUB1 (working 
dilution 1:2,000; Abcam), mouse anti-BUBR1 (working dilution 1:1,000; BD), 
mouse anti-MPS1 (working dilution 1:2,000; Millipore), and rabbit anti– 
P-S10-H3 (working dilution 1:1,000; Abcam).
Video microscopy
Live  cell  imaging  was  performed  using  an  inverted  microscope  (IX70; 
Nikon)  equipped  with  an  incubation  chamber  (Solent  Scientific)  main-
tained at 37°C in an atmosphere of 5% CO2. Videos were acquired using 
a magnification objective of 20 controlled by ScanR software (Olympus).
In vitro kinase assays
Kinase assays were performed in 30 µl (DeMoe et al., 2009). Reaction 
mixes contained 50 µM ATP, 1 mM DTT, 1 mM Na3VO4, 5 µCi -[
32P]ATP, 
1 µg of the appropriate substrate, 1 µl DMSO or drugs dissolved in DMSO, 
and the indicated kinases (typically at a concentration of 5 nM). Reaction 
mixes were incubated for 1 h at 30°C, quenched with SDS loading buffer, 
and resolved on 14% SDS-PAGE. Incorporation of 
32P was visualized by 
autoradiography. Densitometry analysis was performed using ImageJ soft-
ware (National Institutes of Health). IC50 values were calculated from log-
dose response curves using Prism 4 software (GraphPad Software, Inc.).
Purification of mitotic kinases
Human Aurora B
1–344–INCENP
835–903 was expressed in and purified from 
Escherichia coli as a fusion to GST. The protein was purified on reduced 
glutathione (GSH) Sepharose Fast Flow (GE Healthcare), and the GST tag 
was  cleaved  using  PreScission  protease  (GE  Healthcare).  The  cleaved 
product was further purified by size exclusion chromatography in 50 mM 
Tris-HCl, pH 7.6, 150 mM NaCl, and 1 mM DTT. Aurora A–TPX2 (Bayliss 
et al., 2003), a gift of E. Conti (Max Planck Institute of Biochemistry, Mar-
tinsried, Germany) was assayed like Aurora B. Human Nek2A (residues 
1–291) was expressed in E. coli as a fusion to GST. The protein was puri-
fied on GSH Sepharose Fast Flow, and the GST tag was cleaved using   
PreScission protease. The cleaved product was further purified by size ex-
clusion chromatography. NEK2A assays were performed in 50 mM Tris-
HCl, pH 7.5, 10 mM MgCl2, and 10 mM MnCl2 with -casein as a sub-
strate. The Bub1–Bub3 complex was expressed in and purified from Sf9 
insect cells infected with recombinant baculoviruses. The complex was   
isolated on Ni–nitrilotriacetic acid beads and further purified by size ex-
clusion  chromatography.  Bub1–Bub3  kinase  reaction  buffer  contained   
50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10 mM MgCl2, and 1 mM EDTA, 
and histone H3 was used as substrate. Full-length Mps1 was purchased 
from Invitrogen and assayed in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 
10 mM MnCl2, and Mad1–Mad2 complex as a substrate. Human NEK2A 
(residues 1–291) was expressed in E. coli as a fusion to GST. The protein 
was purified on reduced glutathione (GSH) Sepharose Fast Flow, and the 
GST tag was cleaved using PreScission protease. The cleaved product was 
further purified by size exclusion chromatography. NEK2A assays were 
performed in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, and 10 mM MnCl2 
with -casein as a substrate. Human Plk1 (a gift of A. Tarricone, European 
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D. Alessi (University of Dundee, Dundee, Scotland, UK). TAO1 was ex-
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with recombinant baculoviruses. The complex was isolated on Ni–nitrilotri-
acetic acid beads, eluted using 200 mM imidazole, and further dialyzed 
against  PBS.  PRP4  kinase  reaction  buffer  contained  50  mM  Tris-HCl,   
pH 7.6, 150 mM NaCl, 10 mM MgCl2, and 1 mM EDTA, and histone H3 
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was  expressed  in  and  purified  from  E.  coli  as  a  fusion  to  GST.   
GST–Haspin
452–798 was affinity purified on GSH beads (Villa et al., 2009). 
After removal of the tag, the supernatant was further purified on Resource 
Q and a Superdex 200 column (GE Healthcare). Reactions were per-
formed in a solution containing 50 mM Tris, pH 7.6, 10 mM MgCl2,   
150 mM NaCl, and 1 mM EDTA. CDK1–CYCLIN B was a gift of A. Tarri-
cone. Kinase assays were performed in 40 mM Hepes, pH 8, 40 µM   
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